Request Demo

Last update 22 Jun 2026

Isotretinoin

Last update 22 Jun 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

13 cis retinoic acid, Isotretinoin (USP), 异维甲酸

+ [28]

Target

RARs

Action

agonists

Mechanism

RARs agonists(Retinoic acid receptors agonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesOther Diseases+ [2]

Active Indication

NeuroblastomaAcne VulgarisAcneiform Eruptions+ [4]

Inactive Indication

Anal intraepithelial neoplasiaHIV InfectionsHuman Papillomavirus Infection+ [1]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

Leo Pharma, Inc.

Timber Pharmaceuticals LLC

Sun Pharmaceutical Industries Ltd.

+ [3]

Inactive Organization

Patagonia Pharmaceuticals LLC

Cipher Pharmaceuticals, Inc.Hoffmann-La Roche, Inc.

License Organization

Leo US Holding, Inc.

Cipher Pharmaceuticals, Inc.

CHEPLAPHARM Arzneimittel GmbH

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (07 May 1982),

Acneiform Eruptions

RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC20H28O2

InChIKeySHGAZHPCJJPHSC-XFYACQKRSA-N

CAS Registry4759-48-2

250

Clinical Trials associated with Isotretinoin

NCT07629167

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.

Start Date30 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NCT07639073

/ Not yet recruitingPhase 4IIT

Comparing the Efficacy and Safety of Low-Dose Oral Isotretinoin Versus Conventional-Dose in the Treatment of Acne Vulgaris

Background and Purpose:
Acne vulgaris is a common skin condition that can cause significant physical and emotional distress. Oral isotretinoin is a highly effective treatment for severe or persistent acne. While the standard (conventional) dose is effective, it is often associated with side effects like dry skin, chapped lips, and altered labs.
The purpose of this study is to compare a lower daily dose of oral isotretinoin against the conventional daily dose in individuals with acne vulgaris.
What the Study Aims to Find Out:
Researchers want to determine if a low-dose regimen can match the effectiveness (efficacy) of the conventional dose while reducing the frequency and severity of side effects (safety).
Study Design:
Participants will be randomly assigned to receive either the low-dose oral isotretinoin or the conventional-dose oral isotretinoin. Researchers will monitor and compare acne clearance rates, patient satisfaction, and any side effects experienced by the participants throughout the treatment period.

Start Date01 Jul 2026

Sponsor / Collaborator

Pakistan Institute of Medical Sciences

ChiCTR2600125772

/ Not yet recruitingNot ApplicableIIT

Fractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot StudyFractional Radiofrequency Microneedling Combined With Low-Dose Isotretinoin Versus Standard-Dose Isotretinoin in Moderate-to-Severe Acne A Randomized Controlled Pilot Study

Start Date30 May 2026

Sponsor / Collaborator

University of Mosul

100 Clinical Results associated with Isotretinoin

100 Translational Medicine associated with Isotretinoin

100 Patents (Medical) associated with Isotretinoin

5,466

Literatures (Medical) associated with Isotretinoin

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Experts’ view on the management of scalp seborrheic dermatitis in Italy

Review

Author: Guida, Stefania ; Caldarola, Giacomo ; Micali, Giuseppe ; Fulgione, Elisabetta ; Piraccini, Bianca Maria

BACKGROUND:

Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes.

OBJECTIVES AND METHODS:

This study aimed to develop a practical algorithm for SSD management in Italy, by gathering insights from Italian dermatology experts on diagnosis, treatment and long-term management of SSD.

RESULTS:

According to literature review and clinical experience, accurate diagnosis of SSD requires medical history, clinical evaluation, disease severity assessment and trichoscopy. The differentiation of SSD from psoriasis, eczema, and tinea capitis is essential to guide appropriate treatment, which should counteract the main pathogenic mechanisms underlying the disease and be tailored to the severity of clinical manifestations. Topical antifungals are the first-line treatments due to their efficacy in reducing Malassezia colonization. The use of topical anti-inflammatory agents, including corticosteroids, is useful for moderate-to-severe cases, but should be limited due to potential adverse effects. Selenium disulfide may be a useful option for both acute symptom control and long-term maintenance because of its antifungal, sebostatic, keratolytic, and microbiome-restoring properties, associated with a high degree of patient satisfaction. Systemic antifungals may be considered in refractory cases.

CONCLUSION:

This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Sociodemographic, clinical, and behavioral determinants of treatment adherence in acne vulgaris: a multicenter study

Article

Author: Ferhatosmanoğlu, Arzu ; Tosun, Mustafa ; Kalkan, Göknur ; İlhan Erdil, Dilara ; Akpınar Kara, Yeşim ; Kaya Özden, Hatice ; Afacan Yıldırım, Elif ; İnan Yüksel, Esma ; Tümtürk, Mustafa ; Başara Şahin, Rana ; Arıca, İbrahim Etem ; Yıldırım, Mehmet ; Külcü Çakmak, Seray ; Canat, Harbiye Dilek ; Meral, Elif Nur ; Bal Avcı, Elif ; Polat, Mualla ; Yıldırım, Yasemin Aygül ; Kartal, Selda Pelin ; Aksoy Saraç, Gülhan ; Karadağ, Ayşe Serap

BACKGROUND:

This multicenter study aimed to evaluate treatment adherence and satisfaction among patients with acne vulgaris.

METHODS:

A total of 2,349 patients from 18 dermatology centers across Türkiye completed structured questionnaires.

RESULTS:

The participants were predominantly female (79.4%) with a mean age of 21.6 years. Overall, 48% reported consistent adherence to therapy, with significantly lower adherence among males (p < 0.001). The most frequent reasons for nonadherence were forgetfulness (28.7%), dislike of the treatment (26.4%), and reluctance to maintain long-term therapy (21.5%). Treatment adherence was positively associated with higher educational levels (p = 0.006) and greater acne severity (p < 0.001). Logistic regression revealed that systemic oral therapy (OR = 4.37, 95% CI: 3.147-6.086; p < 0.001) and oral isotretinoin (OR = 4.81, 95% CI: 3.379-6.869; p < 0.001) significantly increased adherence compared to topical therapy. Oral treatment was also independently associated with greater satisfaction (OR = 2.33, 95% CI: 1.767-3.095; p < 0.001). Moreover, mild acne severity (OR = 1.67, 95% CI: 1.216-2.297; p = 0.002) and older age (per year; OR = 1.05, 95% CI: 1.020-1.088; p = 0.001) predicted higher satisfaction.

CONCLUSION:

Systemic therapies-particularly oral isotretinoin-were associated with improved adherence and satisfaction.

01 Jul 2026·ANAIS BRASILEIROS DE DERMATOLOGIA

Isotretinoin and serum thyroid parameters: systematic review and meta-analysis

Article

Author: Stewart, Thomas ; Mostafa, Niyaz ; Hong, Esther

BACKGROUND:

Isotretinoin is an effective therapy for acne vulgaris, but its impact on thyroid function remains uncertain, with existing studies reporting inconsistent biochemical changes.

OBJECTIVE:

To assess the effects of oral isotretinoin on serum thyroid function parameters and thyroid antibody levels in patients with acne vulgaris.

METHODS:

A systematic review and meta-analysis of observational studies was conducted according to PRISMA guidelines and prospectively registered (INPLASY202560049). PubMed, Scopus, Embase, and Web of Science were searched from January 1980 to September 2025. Studies reporting serum thyroid parameters before and during isotretinoin therapy were included. Random-effects meta-analyses were performed for parameters reported in more than three studies. Heterogeneity was assessed using the I² statistic, and risk of bias using NIH tools.

RESULTS:

Fifteen studies were included. Meta-analysis showed a small statistically significant increase in thyroid-stimulating hormone after isotretinoin treatment (MD = 0.03, 95% CI 0.02‒0.05, p < 0.001), with significant decreases in thyroxine (MD = -0.19, 95% CI -0.24 to -0.15, p < 0.001) and triiodothyronine (MD = -0.62, 95% CI-0.76 ‒ -0.48, p < 0.001). Heterogeneity was substantial for thyroid-stimulating hormone (I² = 85%) and triiodothyronine (I² = 86%), and moderate for thyroxine (I² = 60%). Evidence regarding thyroid antibodies was limited and inconsistent.

STUDY LIMITATIONS:

Included studies were observational, predominantly single-centre, and heterogeneous in dosing, duration, and laboratory assessments.

CONCLUSIONS:

Isotretinoin is associated with statistically significant alterations in serum thyroid function parameters, though the clinical significance of these changes remains uncertain.

116

News (Medical) associated with Isotretinoin

09 May 2026

·www.prnewswire.com

Lumenis Aesthetics Showcases New Clinical Data Across Skin and Hair Loss Indications at 45th Annual American Society for Laser Medicine and Surgery Conference

New data demonstrates ULTRApulse Alpha® CO2 effectiveness on patients with rhinophyma E‑poster highlights improved skin appearance and lesion clearance outcomes achieved with enhanced Stellar M22™ XPL technology Non-ablative Fractional 1565nm Laser Data supports FoLix™ efficacy in treating patients living with androgenic alopecia YOKNEAM, Israel, May 9, 2026 /PRNewswire/ -- Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced new clinical data from its portfolio of industry-leading devices at the 45th Annual American Society for Laser Medicine and Surgery (ASLMS) Conference taking place in Savannah, Georgia from May 7-9. With Lumenis recognizing its 60th anniversary this year, the four scientific presentations underscore the company's ability to harness cutting-edge laser technologies to exceed patient needs and outcomes, for both skin and hair loss concerns. "At Lumenis, clinical evidence is the engine that drives our innovation forward. The data presented at ASLMS highlights our continued commitment to anticipating what's next in aesthetics and transforming rigorous science into advanced, clinically validated solutions. As patient expectations continue to evolve, our focus remains on arming clinicians with the most cutting‑edge tools available, empowering them to deliver superior, consistent outcomes and confidently shape the future of patient care." Tzipi Ozer-Armon, CEO, Lumenis FoLix Advances Clinical Validation with Studies Demonstrating Efficacy and Mechanism of Action Two pivotal studies to be presented at ASLMS 2026 mark a significant milestone for FoLix, further validating its safety and efficacy as the first and only FDA-cleared non-ablative fractional laser treatment for hair loss. The first, led by Dr. Jennifer Krejci* (Limmer Hair Transplant Center, Texas), represents the largest randomized prospective study to date, demonstrating statistically significant improvements in terminal hair count, total hair count, and follicular density among androgenetic alopecia patients, with up to 82% showing measurable benefit. Complementing these findings, a second study led by Dr. Neil Sadick* (Sadick Dermatology, New York) elucidates FoLix's mechanism of action in human subjects, highlighting its ability to stimulate angiogenesis and dermal remodeling—key biological processes underlying treatment for hair loss. ULTRApulse® CO2 Laser: Challenging Convention in Rhinophyma Treatment Another oral presentation on the ULTRApulse Alpha device highlighted a clinical study** evaluating its use in the treatment of 15 patients with rhinophyma, a condition marked by nasal sebaceous gland hypertrophy and connective tissue fibrosis. While ablative lasers and oral isotretinoin are commonly used therapies, the optimal timing of isotretinoin in combination with laser treatment has previously been unclear. The presented abstract also discussed a unique combination of direct beam application with deep and superficial fractional scanners in treatment of rhinophyma. Results showed significant improvement in Rhinophyma Severity Index scores, 100% patient satisfaction, no delayed healing or abnormal scarring, and 100% of patients stating they would recommend the treatment. Stellar M22™ XPL Repeat Mode: Faster, more comfortable Pulsed Light for Large-Area Treatments The company's e‑poster presentation highlights new clinical data showcasing advancements in Pulsed Light technology using the Stellar M22 platform for the treatment of large areas of photodamaged skin. The single‑center, prospective study evaluated a novel approach combining a high-frequency glide mode (up to 4 Hz) with traditional stamping that enables a smooth gliding technique for faster, more uniform treatments. Results demonstrated that this integrated XPL method was safe and effective in improving skin appearance and achieving lesion clearance across large surface areas, with no evidence of conventional striping or treatment‑related adverse events. Presentation details below: The full results of the e-poster will be made available online for members here after the conference concludes and will be included in an upcoming online-only publication in Lasers in Surgery and Medicine Journal. About Lumenis Lumenis is a global leader in the medical aesthetic and ophthalmic markets and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL), and Radiofrequency (RF). For more than 60 years, Lumenis' ground-breaking products have redefined medical treatments and set technological and clinical gold-standards, revolutionizing existing treatment methods and creating solutions for previously untreatable conditions. About ULTRApulse® Alpha ULTRApulseAlpha is the latest evolution of Lumenis' flagship CO₂ laser platform, designed to deliver exceptional precision, control, and versatility across a wide range of dermatological and aesthetic indications. Built on a legacy of clinically proven ULTRApulse technology, the system features advanced energy delivery modes, customizable treatment settings, and enhanced user interface capabilities to support both ablative and fractional procedures. ULTRApulse Alpha enables physicians to address complex skin conditions—including wrinkles, scars, and lesions—with optimized outcomes and minimal downtime. Engineered for performance and reliability, the platform reflects Lumenis' ongoing commitment to innovation in energy-based medical solutions and to empowering practitioners with cutting-edge tools that elevate patient care. CO2 lasers are intended solely for use by professionals trained in the use of the Carbon Dioxide laser (10.6 μm) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO2 laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO2 systems and accessories operator manuals for a complete list of intended use, contraindications, and risks. The use of Lumenis® CO2 laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6-12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema. About FoLix™ FoLix is a non-ablative fractional laser device indicated for improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I to IV, who are seeking treatment for hair loss. FoLix treatment could cause redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, and pigmentation change. The use of FoLix is contraindicated for patients with any concurrent cancer or history of skin cancer, or pre-cancerous lesions at the treatment area, active infection, chronic fungal or bacterial diseases or chronic dermatological condition of the scalp. See the system user manual for a complete list of contraindications and risks. About Stellar M22 ™ Stellar M22 is a next-generation, multi-application aesthetic platform developed by Lumenis, a global leader in energy-based medical technologies. Building on the legacy of the iconic M22, Stellar M22 integrates four advanced technologies -XPL™, ResurFX® Multi-Spot™ Nd:YAG, and Q-Switched Nd:YAG -into one modular system, enabling treatment of over 30 skin conditions and hair removal across all skin types, ages, and genders. Clinically validated and globally trusted, Stellar M22 is designed to deliver superior patient outcomes with enhanced comfort, speed, and versatility. With over 30,000 systems sold worldwide and more than 150 clinical studies supporting its efficacy, Stellar M22 continues to set the gold standard in aesthetic care. As with any laser or XPL, appropriate care must be taken to ensure safe and proper use. The Stellar M22 operator's manual should be thoroughly reviewed and understood before operating this instrument. Stellar M22, including the Stellar XPL, Multi-Spot Nd:YAG, Q-Switched Nd:YAG and ResurFX, is contraindicated for patients with active infection, viral, fungal or bacterial diseases. It is also contraindicated for patients with skin disorders or inflammatory skin conditions. Be advised that XPL/Laser can cause epidermal injury. The risk increases with greater fluence/energy and skin pigmentation. The use of Stellar M22 could cause redness, swelling, change of pigmentation and scarring. See the system user manual for a complete list of contraindications and risk. *Dr. Krejci and Dr. Sadick are paid spokespersons ** Camacho-Hubbard, I., & Munavalli, G. (2026). Safety and efficacy of fully ablative CO2 laser resurfacing for rhinophyma treatment in patients receiving low-dose oral isotretinoin [E-poster]. American Society for Laser Medicine and Surgery Annual Conference. Media Contact Jacqueline Wickwire, [email protected] SOURCE Lumenis Be. Ltd. 21% more press release views with Request a Demo

Clinical Result

20 Apr 2026

·www.biospace.com

Viatris recalls extended-release Xanax over dissolution test failure

Matt Molloy/Getty Images/iStockphoto Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an analysis revealed an issue that could affect bioavailability. Viatris has recalled one batch of the anti-anxiety medicine Xanax XR in the U.S. because it failed a test of the rate and extent of drug release. The company voluntarily initiated the recall after a batch of bottles containing 60 3-mg tablets of the drug failed dissolution specifications. Drugmakers run dissolution tests to assess the conversion of oral dosage forms into solutions. That conversion determines the bioavailability of the active ingredient and thereby affects the efficacy of the drug product. Viatris found that the dissolution of a batch of extended-release Xanax manufactured in Ireland diverged from the specifications, triggering the Class II recall. The news comes four years after Viatris pulled 110 bottles of Xanax XR from the U.S. market because of out-of-specification results for dissolution. Pfizer, which used to own the drug, recalled 36,000 bottles of immediate-release Xanax in 2012 over dissolution test results. The FDA approved Xanax XR in 2003, months before Pfizer acquired the asset as part of its $60 billion takeover of Pharmacia. An immediate-release formulation of the active ingredient, the benzodiazepine alprazolam, was already available. However, the older product needed to be taken three to four times a day. Xanax XR is taken once daily. Alprazolam was off patent and facing generic competition when the FDA approved Xanax XR. Supported by the extended-release formulation, Pfizer grew sales of its Xanax franchise to $350 million in 2008. By then, generic extended-release alprazolam products were competing for market share. Actavis launched a generic copy of the drug in 2007. Impax Laboratories, which is now part of Amneal Pharmaceuticals, entered the market months after Actavis. Aurobindo Pharma’s generic won FDA approval in 2011. Xanax XR was part of Pfizer until the drugmaker merged its Upjohn business with Mylan to form Viatris in 2020. Viatris reported $139.9 million in Xanax sales last year. Sales have slipped in recent years, falling from $154.8 million in 2023 to $145 million in 2024. FDA FDA mulls compounding for peptides previously flagged over safety risks With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns. April 16, 2026 · 1 min read · Nick Paul Taylor Read more Viatris’ Xanax XR withdrawal was one of 30 drug recalls in the FDA’s latest weekly enforcement report , which also included five recalls by Teva Pharmaceuticals. The company withdrew about 30,000 packages of the acne medicine isotretinoin across two recalls because they were superpotent or subpotent. Teva recalled isotretinoin in January, but the FDA only classified the action this month. Teva’s three other recalls stemmed from the use of an unapproved raw material. The FDA listed Actavis Laboratories as the manufacturer of the recalled batches of Teva’s clonidine transdermal system.

Drug ApprovalAcquisition

16 Apr 2026

·www.prnewswire.com

Assort Health Launches First Voice AI Agents for Dermatology, Enabling Over 5% Increase in Appointment Volume and 200% Labor Capacity

Hundreds of Dermatology Providers Partner with Assort Health to Scale Patient Access Across Complex, High-Volume Care Workflows SAN FRANCISCO, April 16, 2026 /PRNewswire/ -- Assort Health today announced continued expansion of its AI agents platform into dermatology, with additions to its growing customer base, including Legacy Dermatology & Restoration Center and Westlake Dermatology in Texas, MDCS Dermatology in New York and New Jersey, South Jersey Skin Care & Laser Center in New Jersey, and Art of Dermatology in Michigan. Built on a compounding dataset of over 125 million patient interactions across 22 specialties, Assort delivers specialty-trained voice AI agents purpose-built for dermatology practices to manage patient access at scale, improving the patient experience while growing appointment volume and reducing labor costs. Dermatology is one of the most operationally demanding specialties in healthcare. Many practices are effectively operating two businesses on one phone line: medical dermatology billed through insurance and cosmetic procedures collected as cash-pay, each with different scheduling rules, payment workflows, and routing logic. A single practice may treat everything from acne and chronic autoimmune skin disease to surgical skin cancer removal and cosmetic procedures, with each appointment requiring different intake questions, urgency levels, visit lengths, and provider qualifications. Schedulers must quickly interpret vague symptom descriptions ("a weird spot," "something changed," "a bump") and determine whether a patient needs a focused spot check or a full-body skin exam, route them to a provider who can biopsy same-day if needed, and distinguish medical concerns from cosmetic requests, all while balancing strict provider preferences, procedure blocks, and limited availability. Getting the visit type wrong means the wrong slot length, the wrong provider, and a schedule that runs behind all day. These nuances, combined with unpredictable call volumes and the frequency of follow-ups, break down patient access and lead to lost revenue, patient leakage, and delayed care. In many practices, the rules that make scheduling work live in binders, spreadsheets, or the institutional knowledge of experienced front desk staff. While many agentic AI solutions are available on the market, the vast majority aren't built on the years of operational knowledge that makes scheduling work in real practices. They can answer the phone, but aren't able to navigate complex dermatologic care pathways, distinguish urgency levels, or initiate proper next steps. Assort's voice AI agents for patient access integrate directly into EHR and practice management systems to automate both inbound and outbound patient communication with clinical accuracy. Built on the knowledge of 125 million patient interactions, 62 thousand complex protocols, and 1.6 million decision pathways from provider practices across the U.S., the platform delivers scheduling precision for all patient needs. For example, with Assort's platform, dermatology practices prescribing Accutane can schedule follow-up visits within the strict 28–35 day window required for iPLEDGE compliance. The platform also enforces payer-specific global period rules that vary across procedures and insurers. After a Mohs surgery or excision, some payers assign a 0-day global period while others assign 10 or 90 days, and a follow-up visit booked inside that window won't be reimbursed. A scheduler who doesn't catch the difference books the appointment, the claim gets denied weeks later, and the revenue is unrecoverable. Assort applies the correct global period per payer and procedure automatically, so follow-ups are scheduled at the right time and every visit is billable. "Every dermatology practice has its own version of the rules: who does Mohs, who sees cosmetic, which providers biopsy same-day, how the schedule changes on Tuesdays. That knowledge usually lives in the heads of two or three front desk staff. We've spent years encoding that operational knowledge into AI that can actually apply it on every call," said Jon Wang, Founder and Co-CEO of Assort Health. "That's the difference between an AI that answers the phone and one that actually runs your schedule." Legacy Dermatology, a growing Texas-based practice, implemented Assort's voice AI technology after years of struggling with long hold times and missed patient calls despite a fully staffed front desk. Since deployment, Assort's AI agent has helped the practice achieve: 5% growth in total annual appointment volume Significant reduction in hold times, eliminating patient leakage Improved schedule utilization, including same-day openings filled automatically "Our biggest complaint for years was hold time. Now, we're able to get to a patient before the first ring." said Darren Maines, MBA, CMPE, Chief Operations Officer at Legacy Dermatology & Restoration Center. "Assort's technology has not only lightened the burden on our staff, but it has made us more available for our patients." MDCS Dermatology operates nine locations across New York and New Jersey, handling more than 138,000 patient visits a year. Leveraging Assort's AI platform, the practice has: Enabled front office staff to support growing demand and new provider additions, helping drive a 29% increase in total appointment volume over two years Reduced manual coordination required for call and appointment management by approximately 20% Doubled labor capacity, allowing the team to support higher volumes of patient interactions, scheduling, and triage without adding call management resources "We needed a solution that could handle clinical complexity and grow with our practice," said Dr. Parinita Amin, CEO of MDCS Dermatology. "Assort delivers the specialty precision and scalability we were looking for." Assort's expansion into dermatology underscores its broader market momentum as AI agents become foundational infrastructure for the patient journey. What started as voice AI has evolved into a full AI agents platform spanning intake, scheduling, referrals, payments, and ongoing patient engagement, all connected and learning from each interaction. Serving practices across 22 specialties with technology tailored to each, Assort enables healthcare organizations to transform patient access without adding headcount. About Assort Health Assort Health is the AI agents platform built to navigate the complexity of specialty-specific care. Powered by a compounding dataset of over 125 million patient interactions, Assort's technology seamlessly integrates with EHR/PMS and orchestrates the hardest parts of patient access, from intake and high-volume scheduling to referrals, billing, and closing care gaps. Serving over 5,000 providers across hundreds of leading healthcare organizations, from OrthoIndy to Chesapeake Healthcare, Assort drives a 5% increase in total appointment volume, less than 5% call abandonment rate, and a 115% labor capacity increase, all while achieving 4.3/5 patient satisfaction. Assort was recently recognized on the 2026 Enterprise Tech 30 list alongside companies like OpenAI, Anthropic, Stripe, and Ramp. To learn more, visit . Media Contact: Kara Spak, 120/80 MKTG, [email protected] SOURCE Assort Health 21% more press release views with Request a Demo

100 Deals associated with Isotretinoin

External Link

KEGG	Wiki	ATC	Drug Bank
D00348	Isotretinoin	D10BA01 D10AD04	DB00982

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuroblastoma	Japan	Sun Pharma Japan Ltd.	19 Jun 2026
Acne Vulgaris	Canada	Sun Pharmaceutical Industries Ltd.	22 Jun 2023
Cystic acne	Australia	Roche Products Pty Ltd.	05 Dec 1994
Acneiform Eruptions	United States	Hoffmann-La Roche, Inc.	07 May 1982

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autosomal recessive ichthyosis	Phase 3	United States	Leo Pharma, Inc.	21 Jun 2022
Autosomal recessive ichthyosis	Phase 3	Canada	Leo Pharma, Inc.	21 Jun 2022
Autosomal recessive ichthyosis	Phase 3	France	Leo Pharma, Inc.	21 Jun 2022
Autosomal recessive ichthyosis	Phase 3	Germany	Leo Pharma, Inc.	21 Jun 2022
Autosomal recessive ichthyosis	Phase 3	Italy	Leo Pharma, Inc.	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	United States	Leo Pharma, Inc.	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Canada	Leo Pharma, Inc.	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	France	Leo Pharma, Inc.	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Germany	Leo Pharma, Inc.	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Italy	Leo Pharma, Inc.	21 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2026	Not Applicable	Acne Vulgaris	764	Oral Isotretinoin + H9-antihistamines	vnqfsydpnh(aavijcirsc): RR = 0.83 (95.0% CI, 0.69 - 0.99), P-Value = 0.04	Positive	27 Mar 2026
				Oral Isotretinoin
AAD2026	Not Applicable	Acne Vulgaris	1,338	Isotretinoin	elojkibiiw(btvftajhem) = jeivtuwytg iwshiienwi (aadtqgeezq )	Positive	27 Mar 2026
				Topical monotherapy	elojkibiiw(btvftajhem) = ixahchicqq iwshiienwi (aadtqgeezq )
AAD2026	Not Applicable	Acne Vulgaris	1,658	Traditional isotretinoin	iebosxdejj(bhxguaugip) = gjzuicurfa mzgstzroro (snaflucngd )	Positive	27 Mar 2026
				Intermittent isotretinoin	iebosxdejj(bhxguaugip) = aaxxjpramj mzgstzroro (snaflucngd )
AAD2026	Not Applicable	Pseudofolliculitis Barbae	23,760	Eflornithine	djwzwovjhr(sztxogzeaj) = lskjmlyyxy tyjxukifis (gvpzcmajuj, 14.0) View more	Negative	27 Mar 2026
AAD2026	Not Applicable	Acne Vulgaris	410	Topical retinoids	wviewmqehz(kunjupqgkb) = lgtwlunhtd hhzmcrqpzc (rclcmbdtnw ) View more	Negative	27 Mar 2026
AAD2026	Not Applicable	Skin aging	120	Oral Isotretinoin	qkfamlqtsu(wffozbtgyv) = mjbjifbglo uqhazbynwe (atsypcvsmv ) View more	Positive	27 Mar 2026
NCT04361422 (Pubmed \| Contemp Clin Trials)	Phase 2	COVID-19 ACE2 protein	106	Isotretinoin + Standard Care	fuwhivzfyc(ucrapmtghi) = The main adverse event reported during the therapeutic duration was the dryness of the skin, which was of acceptable tolerability through skin care instructions to the patients. atdocodbax (bbkyifrzvg ) View more	Positive	01 Mar 2025
				Standard Care
NCT03076021 (CTgov)	Phase 4	-	33	isotretinoin (Pre-isotretinoin)	gxgjcgqczt(lnziypymjy) = ehuhcvoroi udewucxxsc (mptduchozz, ipjmbpkmfy - frubwejlmz) View more	-	28 Jan 2025
				Isotretinoin (With Isotretinoin)	gxgjcgqczt(lnziypymjy) = shkagwkdjj udewucxxsc (mptduchozz, tbhemiadsm - krsezsfpkw) View more
NCT05295732 (ASCEND, NEWS) Manual	Phase 3	Ichthyosis	-	-	dvpixbfnoc(mmdeiweofl) = not met sstxfwqkvj (caixilqpor ) Not Met View more	Negative	22 Aug 2024
				-
EULAR2024	Not Applicable	Low Back Pain	-	Isotretinoin use for acne vulgaris	bjohwvxmrx(oqqothgrix) = 59 patients who developed inflammatory low back pain after isotretinoin use were included vbwvqsaqpv (xpzyvwrram ) View more	-	05 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis